4h
Hosted on MSNHims & Hers Retail Traders Eye Robust Post-Earnings Rebound Following Stock’s Worst Drop On Semaglutide UpdateHims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...
Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Domino's Pizza -- one of the best performing stocks of the last two decades -- headlines Monday's slate of earnings. Hims & Hers Health -- [whose shares tumbled Friday after Novo Nordisk said a shorta ...
We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely ...
Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...
HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...
Hims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized ...
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
Hims’s acquisition of Trybe Labs will put it in competition with health industry juggernauts such as Labcorp and Quest ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results